A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Local Institution - 0005, Sydney

Local Institution - 0002, Camberwell

Local Institution - 0015, New York

Local Institution - 0003, Berlin

Local Institution - 0006, Kiel

Local Institution - 0013, Cleveland

Local Institution - 0036, Arlington Heights

Local Institution - 0016, Shreveport

Local Institution - 0020, Oklahoma City

Local Institution - 0039, Lubbock

Local Institution - 0032, Garland

Local Institution - 0033, Southlake

Local Institution - 0014, San Diego

Local Institution - 0026, Chapel Hill

Local Institution - 0007, Edmonton

Local Institution - 0025, London

Local Institution - 0008, Vaughan

Local Institution - 0019, Dresden

Local Institution - 0009, Amsterdam

Local Institution - 0031, Warsaw

Local Institution - 0030, Warsaw

Local Institution - 0029, Bydgoszcz

Local Institution - 0028, Bydgoszcz

Local Institution - 0011, San Juan

Local Institution - 0023, London

Local Institution - 0027, Cambridge